The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Zhaozhen Wu(Nankai University), Yi Hu(Nankai University), Haitao Tao(Chinese People's Liberation Army), Shixue Chen(Chinese PLA General Hospital), Jinliang Wang(Chinese PLA General Hospital), Xuan Zheng(Chinese PLA General Hospital), Ziwei Huang(Nanjing University of Chinese Medicine), Pengfei Cui(Chinese PLA General Hospital), Sujie Zhang(Chinese PLA General Hospital), Yuanyu Qian(Chinese People's Liberation Army), Di Huang(Qilu Hospital of Shandong University), Junxun Ma(Chinese People's Liberation Army), Zhefeng Liu(Chinese People's Liberation Army)
Cited by 64
Related Papers
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
|Molecular Cancer Therapeutics|2006|186
Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies
|Journal of Biological Chemistry|2001|138
Bio-template synthesis of Mo-doped polymer carbon nitride for photocatalytic hydrogen evolution
|Applied Catalysis B: Environmental|2019|133
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
|Frontiers in Oncology|2021|125
Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with d-Peptides Derived from Chemokines
|Journal of Biological Chemistry|2002|117